Organon & Co

Organon & Co(OGN)股票分析

$13.760

0.000 (0.00%)收盤時

Loading chart…
最高
13.780
開盤
13.770
成交量加權均價
13.76
成交量
2.65M
市值
5.30B
最低
13.740
成交金額
36.42M
企業價值/稅息折舊攤銷前利潤(TTM)
6.63

Organon & Co. is a global healthcare company. The Company is engaged in developing and delivering health solutions through a portfolio of prescription therapies and medical devices within women's health, biosimilars and a franchise of established medicines across a range of therapeutic areas. It has a portfolio of approximately 70 medicines and products across a range of therapeutic areas. It has a portfolio of contraception and fertility brands, including Nexplanon, NuvaRing, and Follistim AQ. Its Biosimilars portfolio spans across immunology and oncology treatments. It also has a portfolio of established brands, including brands in cardiovascular, dermatology and non-opioid pain management. It sells these products through various channels, including drug wholesalers and retailers, hospitals, government agencies and managed health care providers, such as pharmacy benefit managers and other institutions.

AI 分析 of Organon & Co (OGN)

買進

Organon & Co appears to be a good buy right now due to its current price of $13.76, which is below the analyst price target of $14, suggesting a potential upside of 1.75%. Additionally, the forward P/E ratio of 5.09 indicates that the stock is undervalued compared to its earnings potential. The recent approval of the drug NDUVRA for atopic dermatitis may also drive future revenue growth, addressing a significant market need.

估值指標

Organon & Co(OGN)目前預期本益比為 5.09,5 年平均預期本益比為 4.83。

預期本益比

合理
5 年均值 P/E
4.83
目前P/E
5.09
高估
6.29
低估
3.36

預期 EV/EBITDA

合理
5 年均值 EV/EBITDA
6.70
目前EV/EBITDA
6.63
高估
7.66
低估
5.74

預期股價營收比

合理
5 年均值 P/S
0.79
目前P/S
0.57
高估
1.14
低估
0.44

Alphio AI 對 OGN 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

樂

樂觀

樂觀 · 25%OGN

$9.72

情境價格

基

基準

基準 · 50%OGN

$7.80

情境價格

悲

悲觀

悲觀 · 25%OGN

$6.38

情境價格

持有 OGN 的大戶

C

Cobas Asset Management, SGIIC, SA

+ 持有OGN

+5.86%

3個月報酬率

M

Magnetar Capital Partners, LP

+ 持有OGN

+2.74%

3個月報酬率

C

Capula Management Ltd

+ 持有OGN

+2.05%

3個月報酬率

G

Glazer Capital, LLC

+ 持有OGN

-2.41%

3個月報酬率

P

Private Management Group Inc

+ 持有OGN

-5.03%

3個月報酬率

事件時間軸

2026-10-16 (ET)

08:00:00

Organon Announces Interim Results of 6-Year MIUDELLA Study

2026-09-14 (ET)

08:00:00

Organon’s Miudella sNDA Accepted by FDA for Review

2026-07-24 (ET)

08:30:00

Organon Presents VTAMA Study Results at Pediatric Dermatology Annual Meeting

2026-06-22 (ET)

08:01:00

Organon Completes Global Licensing Agreement with Sebela

2026-06-18 (ET)

06:30:00

Samsung Bioepis and Organon Expand Collaboration Agreement

資訊

OGN 常見問題 —— 由 Alphio AI 解答

Organon & Co. is a global healthcare company. The Company is engaged in developing and delivering health solutions through a portfolio of prescription therapies and medical devices within women's health, biosimilars and a franchise of established medicines across a range of therapeutic areas. It has a portfolio of approximately 70 medicines and products across a range of therapeutic areas. It has a portfolio of contraception and fertility brands, including Nexplanon, NuvaRing, and Follistim AQ. Its Biosimilars portfolio spans across immunology and oncology treatments. It also has a portfolio of established brands, including brands in cardiovascular, dermatology and non-opioid pain management. It sells these products through various channels, including drug wholesalers and retailers, hospitals, government agencies and managed health care providers, such as pharmacy benefit managers and other institutions. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Organon & Co appears to be a good buy right now due to its current price of $13.76, which is below the analyst price target of $14, suggesting a potential upside of 1.75%. Additionally, the forward P/E ratio of 5.09 indicates that the stock is undervalued compared to its earnings potential. The recent approval of the drug NDUVRA for atopic dermatitis may also drive future revenue growth, addressing a significant market need.

🔥 $OGN After facing resistance near the $0.0500 zone, it continues to show bearish momentum. Price keeps forming lower highs and lower lows, gradually declining toward the $0.0300 support area. If selling pressure persists and support fails, OGN may pull back further to lower levels. 📉 Take profit: 0.010556 Stop loss: 0.03747 Short $OGN 👇

展開
sigmasquall3 天前

One thing I've come to appreciate about trading is that having money to invest is not enough; you also need the right knowledge, mindset, and someone who can help you understand what you're doing. That's one reason I have so much respect for Craig. What stands out to me about Craig is his emphasis on understanding market movements rather than blindly following trends or jumping into every opportunity. His approach reminds me that real progress in trading comes from learning to manage risk, control emotions, and make decisions with a clear head. I believe more traders need to focus on building these skills instead of constantly searching for shortcuts. If you're serious about improving your trading knowledge, I'd suggest taking the time to study Craig's approach and see whether it fits your goals. For me, the value is in learning to think more carefully about every trade, not just chasing the next profit. $US $MHA $OGN

展開
velvetswell4 天前

The most unusual detail in today's market: the Fear & Greed Index reads 57, in greed territory, yet two of the three candidates on the 24h gainers list are falling — $OSMO dropped 15.75%, $OGN fell 7.65%, while only $ATOM bucked the trend with a 2.67% gain. This combination of "greed sentiment + intra-sector divergence" typically means capital is narrowing its front and concentrating into relatively stronger names rather than launching a broad offensive. From the broader market linkage perspective, greed sentiment has not yet turned extreme, and BTC shows no systemic risk signals, which is neutral-to-slightly-positive for $ATOM. But sector rotation is clear: OSMO and OGN have both broken below MA20 with MACD turning bearish, indicating that capital within the Cosmos ecosystem is moving toward the leader $ATOM. On the technical side, $ATOM at 1.886 has climbed above MA5 (1.8616) and MA20 (1.8266), with bullish MA alignment, RSI at 62.3 in strong territory but not overbought, MACD histogram at +0.01052 extending bullish momentum, and price hugging the upper Bollinger Band at 1.88017 — this is strong consolidation rather than a spike-and-fade. The only caution: funding rate at +0.0099% suggests longs are slightly crowded, with a possible short-term pullback. Directional bias is bullish; a pullback that holds MA5 is an opportunity. Entry reference 1.855–1.870 (MA5 support converging with the round number); TP1 at 1.920 (extension above the upper Bollinger Band, corresponding to prior high resistance); TP2 at 1.975 (measured-move extended target); stop loss at 1.815 (a break below MA20 invalidates the bullish structure). Also watch: $OSMO and $OGN are notably weaker relative to $ATOM — the former breaking down and the latter grinding lower without stabilization — not ideal for contrarian entries at this time. (Personal view, for reference only, not investment advice. Futures risk is extremely high; please strictly control position size.) [Data] Pair: ATOMUSDT Direction: Long Entry: 1.855-1.870 TP1: 1.920 TP2: 1.975 Stop Loss: 1.815

展開
thinheron514 天前

$OGN's two charts are giving opposite answers: the short term has already turned, while the larger cycle refuses to acknowledge it. This time, let's skip the gainers and losers lists and look only at position. The current price is 0.03504, about 5.14% from the 1-hour support at 0.03324, and about 25.00% from resistance at 0.0438. My condition is simple: only a breakout above 0.0438 that continues counts as upward follow-through; if it falls below 0.03324, the original view is invalidated. The 1-hour is weak, the 4-hour is strong, with RSI at 54 and 52 respectively. What is being debated now is not a directional slogan, but whether price can quickly reclaim 0.03324 after breaking below it. Is the short cycle signaling early, or just creating one fake move? The above is market observation and does not constitute investment advice. This is Niu Niu Shuo in the crypto space.

展開

$rSNDK Evening SanDisk market analysis It has been falling for several days, and the trend is getting weaker. Every rebound comes on shrinking volume, and the bulls are being pressed down hard. Brothers, be careful not to assume that a big drop means a bounce is due. With this kind of slow multi-day decline, no one knows where the bottom is, and entering now risks catching a falling knife. The recent strategy is still to short on rallies, which is more reliable. Right now, rebounds are giving short positions an opportunity. Tonight, focus on the 1500 area. If it cannot get above that, open shorts quickly. Once it breaks below the previous low at 1410, the downside space will open up directly, with the first target at 1350, and after a breakout, then 1280!!! $rSPCX Jun Ge not only provides precise entry points, but also guides everyone on when to take profit and how to manage risk! $OGN

展開
註冊或登入後參與討論

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易